ClinicalTrials.gg
AvailableNCT07215832KEAPUpdated Mar 2, 2026

Karyopharm Expanded Access Program for Selinexor

An expanded access record providing selinexor in Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL) and Sarcoma, sponsored by Karyopharm Therapeutics Inc. Available. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Karyopharm Therapeutics Inc · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Sex
All
01

Study summary

KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.

02

Conditions studied

  • Multiple Myeloma
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Sarcoma
  • Neuroglioblastoma
  • Peripheral T-cell Lymphoma
  • Endometrial Cancer
  • Myelofibrosis
  • Other

Keywords

  • selinexor
03

In context

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Lead sponsor

Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Exclusion criteria

Exclusion Criteria:

-

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07215832
Collaborators
Caligor Coghlan (CalCog)
Responsible party
Sponsor
First posted
Oct 14, 2025
Last update
Mar 2, 2026

Study contacts

Karyopharm Medical Information
Contact
keap.admin@karyopharm.com
(888) 209-9326
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion